Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Angel R. Fuentes-Pesquera"'
Autor:
Peter J. Connolly, Jonathan M. Blevitt, Virna B. Borowski, Kenneth R. LaMontagne, Jeannene Butler, Lee M. Greenberger, Shenlin Huang, Angel R. Fuentes-Pesquera, Ronghua Li
Publikováno v:
Angiogenesis. 12:287-296
Angiogenesis is a complex process that relies on a variety of growth factors and signaling pathways to stimulate endothelial cell responses and establish functional blood vessels. Signaling through the vascular endothelial growth factor (VEGF) recept
Autor:
Catherine A. Rugg, Angel R. Fuentes-Pesquera, Steven A. Middleton, Stuart Emanuel, Peter J. Connolly, Richard S. Alexander, Terry V. Hughes, Prabha Karnachi, Harold R. O’Grady
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:5130-5133
A novel series of 7-[1H-indol-2-yl]-2,3-dihydro-isoindol-1-ones designed to be inhibitors of VEGF-R2 kinase was synthesized and found to potently inhibit VEGF-R2 and Aurora-A kinases. The structure-based design, synthesis, and initial SAR of the seri
Autor:
Sandra Moreno-Mazza, Stuart Emanuel, Peter J. Connolly, Niranjan Pandey, Robert H. Gruninger, Lee M. Greenberger, Virna Borowski, Steven A. Middleton, Terry V. Hughes, Jennifer R. Story, Cheryl Napier, Jeannene Butler, Mary Adams, Beth A. Hollister, Catherine A. Rugg, Angel R. Fuentes‐Pesquera
Publikováno v:
Molecular Pharmacology. 73:338-348
JNJ-28871063 is a potent and highly selective pan-ErbB kinase inhibitor from a novel aminopyrimidine oxime structural class that blocks the proliferation of epidermal growth factor receptor (EGFR; ErbB1)- and ErbB2-overexpressing cells but does not a
Autor:
Yanhua Lu, Lee M. Greenberger, George Chiu, Yang Yu, Angel R. Fuentes-Pesquera, Peter J. Connolly, Steven A. Middleton, Mary Adams, Stuart Emanuel, Shenlin Huang, Xun Li, Ronghui Lin, Shengjian Li, Robert H. Gruninger
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:4297-4302
A series of 3,5-disubstituted pyrazolo[3,4-b]pyridine cyclin-dependent kinase (CDK) inhibitors was synthesized. These compounds showed potent and selective CDK inhibitory activities and inhibited in vitro cellular proliferation in cultured human tumo
Autor:
Ronghua Li, Angel R. Fuentes-Pesquera, David Festus Charles Moffat, Jeremy Martin Davis, Peter J. Connolly, Steven A. Middleton, Mary Adams, Stuart Emanuel, Jabed Seraj, Robert H. Gruninger, Shenlin Huang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:2179-2183
The series of 2-amino-4-aryl-5-chloropyrimidines was discovered to be potent for both VEGFR-2 and CDK1. Described here are the chemistry for analogue synthesis, SAR study, and its kinase selectivity prolifing. The full rat PK data and in vivo efficac
Autor:
Cheryl Napier, Angel R. Fuentes-Pesquera, Steven K. Wetter, Beth A. Hollister, Linda K. Jolliffe, Steven A. Middleton, Peter J. Connolly, Catherine A. Rugg, Robert H. Gruninger, Ronghui Lin, Walter W. Kruger, Stuart Emanuel
Publikováno v:
Cancer Research. 65:9038-9046
Modulation of aberrant cell cycle regulation is a potential therapeutic strategy applicable to a wide range of tumor types. JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora
Autor:
Stuart Emanuel, Yanhua Lu, Ronghui Lin, Shenlin Huang, Linda Jolliffe, Steven A. Middleton, Robert H. Gruninger, Peter J. Connolly, Steven K. Wetter, William V. Murray, Catherine A. Rugg, Angel R. Fuentes-Pesquera
Publikováno v:
Journal of Medicinal Chemistry. 48:4208-4211
A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in
Autor:
Angel R. Fuentes-Pesquera, Steven A. Middleton, Aihua Wang, Yan Zhang, Catherine A. Rugg, Robert H. Gruninger, William V. Murray, Linda Jolliffe, Stuart Emanuel, Alan Deangelis, Peter J. Connolly, Xin Chen, Gee-Hong Kuo
Publikováno v:
Journal of Medicinal Chemistry. 48:4535-4546
On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474
Autor:
Xin Chen, Gee-Hong Kuo, Linda Jolliffe, Robert H. Gruninger, Angel R. Fuentes-Pesquera, Steven A. Middleton, Dana L. Johnson, Aihua Wang, Rui Zhang, Stuart Emanuel, William V. Murray, Peter J. Connolly, Alan Deangelis, Jan L. Sechler
Publikováno v:
Journal of Medicinal Chemistry. 48:1886-1900
Pathological angiogenesis is associated with disease states such as cancer, diabetic retinopathy, rheumatoid arthritis, endometriosis, and psoriasis. There is much evidence that direct inhibition of the kinase activity of vascular endothelial growth
Autor:
Niranjan Pandey, Angel R. Fuentes-Pesquera, Eva Binnun, Sigmond G. Johnson, Steven K. Wetter, Sandra Moreno-Mazza, Terry V. Hughes, William V. Murray, Steven A. Middleton, Peter J. Connolly, Ronghui Lin, Mary Adams
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(8)
2,7-Diamino-thiazolo[4,5-d]pyrimidine analogues were synthesized as novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Representative compounds showed potent and selective EGFR inhibitory activities and inhibited in vitro cellu